Recombinant LIV-1 (Ladiratuzumab Biosimilar) 抗体
-
- 抗原 See all LIV-1 (Ladiratuzumab Biosimilar) products
- LIV-1 (Ladiratuzumab Biosimilar)
- 抗体类型
- Recombinant Antibody
- 适用
- 人
-
宿主
-
Human
- Expression System
- CHO Cells
-
克隆类型
- 单克隆
-
标记
- This LIV-1 (Ladiratuzumab Biosimilar) antibody is un-conjugated
- 应用范围
- ELISA, Bio-Layer Interferometry (BLI), Flow Cytometry (FACS), Functional Studies (Func), Surface Plasmon Resonance (SPR)
- 原理
- Anti-LIV-1 / SLC39A6 Reference Antibody (ladiratuzumab)
- 序列
- QVQLVQSGAE VKKPGASVKV SCKASGLTIE DYYMHWVRQA PGQGLEWMGW IDPENGDTEY GPKFQGRVTM TRDTSINTAY MELSRLRSDD TAVYYCAVHN AHYGTWFAYW GQGTLVTVSS ASTKGPSVFP LAPSSKSTSG GTAALGCLVK DYFPEPVTVS WNSGALTSGV HTFPAVLQSS GLYSLSSVVT VPSSSLGTQT YICNVNHKPS NTKVDKKVEP KSCDKTHTCP PCPAPELLGG PSVFLFPPKP KDTLMISRTP EVTCVVVDVS HEDPEVKFNW YVDGVEVHNA KTKPREEQYN STYRVVSVLT VLHQDWLNGK EYKCKVSNKA LPAPIEKTIS KAKGQPREPQ VYTLPPSRDE LTKNQVSLTC LVKGFYPSDI AVEWESNGQP ENNYKTTPPV LDSDGSFFLY SKLTVDKSRW QQGNVFSCSV MHEALHNHYT QKSLSLSPG,DVVMTQSPLS LPVTLGQPAS ISCRSSQSLL HSSGNTYLEW YQQRPGQSPR PLIYKISTRF SGVPDRFSGS GSGTDFTLKI SRVEAEDVGV YYCFQGSHVP YTFGGGTKVE IKRTVAAPSV FIFPPSDEQL KSGTASVVCL LNNFYPREAK VQWKVDNALQ SGNSQESVTE QDSKDSTYSL SSTLTLSKAD YEKHKVYACE VTHQGLSSPV TKSFNRGEC
- 产品特性
- Anti-LIV-1 / SLC39A6 Reference Antibody (ladiratuzumab) is expressed from CHO. The heavy chain type is huIgG1, and the light chain type is hukappa. It has a predicted MW of 145.5 kDa.
- 纯度
- >95 %
- 亚型
- IgG1
-
-
- 应用备注
- Optimal working dilution should be determined by the investigator.
- 说明
-
Therapeutic Agents by Target and Mechanism: LIV-1 inhibitors
- 限制
- 仅限研究用
-
- 状态
- Lyophilized
- 浓度
- 1 mg/mL
- 缓冲液
- 25 mM histidine, 8 % sucrose, 0.01 % Tween80 pH 6.2
- 储存条件
- 4 °C,-80 °C
- 储存方法
- +4°C,-80°C
-
- 抗原
- LIV-1 (Ladiratuzumab Biosimilar)
- Abstract
- LIV-1 (Ladiratuzumab Biosimilar) 产品
- 物质类
- Biosimilar
- 分子量
- 145.5 kDa
- UniProt
- Q13433
-